Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial.

A short-lived anti-PD-L1 antibody was safe and well tolerated in early Alzheimer's disease patients at doses up to 30 mg/kg, supporting further clinical development.

• Why it matters: Alzheimer's progression involves neuroinflammation that the aging immune system cannot resolve, highlighting the need for immune-modulating therapies to slow disease progression.
• What they did: A phase 1b trial with 40 participants tested four doses of the engineered IBC-Ab002 antibody administered every three months, focusing on safety and tolerability, with exploratory biomarker analysis.
• The result: The treatment was safe with no serious adverse events, and preliminary biomarker trends at week 48 suggest potential neuroprotective effects, enabling further research in systemic immunotherapy for AD.